白细胞介素6水平升高与终末期肝病患者90天和1年死亡率增加相关
该回顾性观察性队列研究纳入474例在德国接受肝移植评估的终末期肝病患者,分析白细胞介素6(IL6)、C反应蛋白(CRP)和白细胞计数(WBC)与死亡率的关系。结果显示IL6水平与90天和1年死亡率相关,其预测价值与MELD或MELD-Na评分相当,且高于CRP或WBC。
要点
- IL6水平低于第一四分位数(<5.3 pg/mL)的患者1年内无死亡。
- IL6水平最高四分位数(≥37.0 pg/mL)患者1年死亡率为67.7%。
- IL6对90天死亡率的预测价值(AUROC 0.940)高于CRP(0.866)和WBC(0.773)。
核心结论
- 回顾性分析发现,终末期肝病患者高血IL6水平与90天和1年死亡率相关;其预测价值与MELD或MELD-Na评分相当,且高于CRP或WBC水平。
- 作者建议需进一步研究在不同队列中确认这些结果。
研究设计与样本
- 回顾性观察性队列研究,纳入474例在德国接受肝移植评估的终末期肝病患者(63.5%男性;中位年龄56.9岁),随访至少1年。
- 收集CRP、IL6和WBC的血液水平数据,并与MELD评分和MELD-Na评分进行比较分析。
- 按IL6、CRP、WBC水平及MELD评分的四分位数分组进行生存分析,使用对数秩检验和Cox比例风险回归模型比较组间差异,并计算受试者工作特征曲线下面积(AUROC)。
主要发现
- IL6水平低于第一四分位数(<5.3 pg/mL)的患者1年内无死亡;IL6水平最高四分位数(≥37.0 pg/mL)的患者1年死亡率为67.7%。
- MELD评分低于8.7的患者1年死亡率为0.9%,而MELD评分≥18.0的患者1年死亡率为67.4%。
- IL6对90天死亡率的预测价值(AUROC 0.940)高于CRP(AUROC 0.866)(P = .009)或WBC(AUROC 0.773)(P < .001)。
- MELD评分与90天死亡率相关(AUROC 0.933)(P = .756),MELD-Na评分亦相关(AUROC 0.946)(P = .771)。
- IL6与1年死亡率的相关性(AUROC 0.916)大于肝脏合成或解毒标志物国际标准化比值(AUROC 0.839)(P = .007)或胆红素(AUROC 0.846)(P = .007)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Organ allocation for liver transplantation is based on prognosis, using the model for end-stage liver disease (MELD) or MELD including serum sodium (MELD-Na) score. These scores do not consider systemic inflammation and septic complications. Blood level of C-reactive protein (CRP), in addition to the MELD score, associates with mortality in patients with end-stage liver disease, whereas levels of interleukin 6 (IL6) have not been systematically studied. METHODS: We performed a retrospective observational cohort study of 474 patients with end-stage liver disease (63.5% male; median age, 56.9 years), evaluated for liver transplantation in Germany, with at least 1 year of follow up. Data were collected on blood levels of CRP, IL6, and white blood cell count (WBC). Findings were analyzed in relation to mortality and compared with patients' MELD scores and MELD-Na scores. For survival analysis, the cohort was divided into quartiles of IL6, CRP, and WBC levels, as well as MELD scores. Log-rank test and the Cox proportional hazards regression model were used to compare the groups, and area under the receiver operating characteristic (AUROC) values were calculated. RESULTS: Blood levels of IL6 and MELD scores associated with mortality: none of the patients with levels of IL6 below the first quartile (below 5.3 pg/mL) died within 1 year. In contrast, 67.7% of the patients in the highest quartile of IL6 level (37.0 pg/mL or more) died within 1 year. MELD score also correlated with mortality: among patients with MELD scores below 8.7, 0.9% died within 1 year, whereas in patients with MELD scores of 18.0 or more, 67.4% died within 1 year. The predictive value of level of IL6 (AUROC, 0.940) was higher than level of CRP (AUROC, 0.866) (P = .009) or WBC (AUROC, 0.773) (P < .001) for 90-day mortality. MELD scores associated with 90-day mortality (AUROC, 0.933) (P = .756) as did MELD-Na score (AUROC, 0.946) (P = .771). Level of IL6 associated with 1-year mortality (AUROC, 0.916) to a greater extent than liver synthesis or detoxification markers international normalized ratio (AUROC, 0.839) (P = .007) or bilirubin (AUROC 0.846) (P = .007). Level of IL6 was an independent, significant risk factor for mortality after adjustment for MELD score, MELD-Na score, level of CRP, or WBC. CONCLUSIONS: In a retrospective analysis, we found high blood levels of IL6 to associate with 90-day and 1-year mortality in patients with end-stage liver disease; its predictive value was comparable to that of MELD or MELD-Na score, and was higher than that of level of CRP or WBC. Further studies should be performed to confirm the results in different cohorts.
引用
- Remmler J, Schneider C, Treuner-Kaueroff T, et al. Increased Level of Interleukin 6 Associates With Increased 90-Day and 1-Year Mortality in Patients With End-Stage Liver Disease. Clin Gastroenterol Hepatol. 2017. PMID: 28919544. doi:10.1016/j.cgh.2017.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。